Home › Funds › DV EQUITIES, LLC › SABS

DV EQUITIES, LLC position in SABS

SAB BIOTHERAPEUTICS INC · Health Care

DV EQUITIES, LLC reported holding 400,000 shares of SABS (SAB BIOTHERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$1.3M, representing 0.25% of its reported portfolio and ranking #45 among its reported holdings. DV EQUITIES, LLC has disclosed SABS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

Latest position (Q3 2026)400.00K sh
Reported value held$1.27M
Portfolio Weight0.25%
First reportedQ2 2026
Last changeHold
Updated2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

How DV EQUITIES, LLC's SABS position evolved

DV EQUITIES, LLC first disclosed a stake in SABS in Q2 2026 at 400,000 shares (US$1.6M). Across 2 filings, DV EQUITIES, LLC held the position steady without any share-count change. The most recent filing (Q3 2026) shows 400,000 shares valued at US$1.3M.

Quarter by quarter

QuarterSharesValueChange
Q2 2026 400.00K $1.56M New
Q3 2026 400.00K $1.27M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SABS and 13F data

SABS (SAB BIOTHERAPEUTICS INC) is a Health Care company. 71 other funds we track also report a position in SABS — the largest reported positions include Caligan Partners LP (US$27.7M), Vivo Capital, LLC (US$21.9M), PERCEPTIVE ADVISORS LLC (US$21.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SABS

All SABS fund holders →

FAQ

How long has DV EQUITIES, LLC held SABS?

DV EQUITIES, LLC has disclosed SABS holdings in 2 of the last 2 reported quarters, going back to Q2 2026.

What is DV EQUITIES, LLC's current position in SABS?

As of Q3 2026, DV EQUITIES, LLC holds 400.00K shares of SABS (SAB BIOTHERAPEUTICS INC), valued at $1.27M, representing 0.25% of its reported portfolio and ranking #45.

Has DV EQUITIES, LLC been buying or selling SABS?

In the latest 13F filing (Q3 2026), DV EQUITIES, LLC held unchanged its position in SABS.

Which other funds hold SABS?

Other major institutional holders of SABS include Caligan Partners LP, Vivo Capital, LLC, PERCEPTIVE ADVISORS LLC, among 71 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.